Cohance Lifesciences Ltd · NSE:COHANCE
Cohance Lifesciences — Suven Pharmaceuticals — Q1 FY24 Earnings Presentation
22 slides from Cohance Lifesciences's earnings presentation, 2023
Slide 1: Suven Pharma Earnings Presentation Q1 FY24
SUVEN PHARMA Earnings Presentation Q1 FY24
Slide 2: Risk Statement
Risk Statement Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this presentation may be forward-looking statements that involve a number of risks and uncertainties. Although Suven Pharma attempts to be accur
Slide 3: Table of Contents
4 14 Table of Operation & Financial Company Background Contents Performance Q1 FY24 3
Slide 4: Operation & Financial Performance Q1 FY24
Operation & Financial Performance Q1 FY24 4
Slide 5: Businesswise data
Businesswise data CDMO Pharma CDM O Spec Chem Formulations & Other Ser vices 256.45 117.35 245.97 35.2 210.23 72.74 75.35 22.7 11.22 Q1FY23 Q4FY23 Q1FY24 Q1FY23 Q4FY23 Q1FY24 Q1FY23 Q4FY23 Q1FY24 Note: Figures in Rs. Crore 5
Slide 6: Financial Snapshot
Financial Snapshot Q1FY24 Q1FY23 Growth in Growth in Growth in Revenue EBITDA PAT -5.61% -2.94% -4.51% 1.25% 8.64% 8.98% Comparison with immediate previous quarter and same quarter of previous year 6
Slide 7: Key Ratios
Key Ratios Q1FY24 Q1FY23 EBIT to EBITDA to PAT to Income Income Income 47.67% 50.82% 35.10% 44.35% 47.37% 32.61% 7
Slide 8: Financials Comparison - Q1FY24 to earlier periods
Financials Comparison - Q1FY24 to earlier periods Revenue EBIDTA PAT EPS 3,751 1,854 1,302 5.1 3,541 1,799 1,243 3,497 1,656 1,141 4.9 RUPEES MN RUPEES MN RUPEES MN RUPEES 4.5 Q1FY23 Q4FY23 Q1FY24 Q1FY23 Q4FY23 Q1FY24 Q1FY23 Q4FY23 Q1FY24 Q1FY23 Q4FY23 Q1FY24 8
Slide 9: Financials Comparison - Q1FY24 to earlier periods
Financials Comparison - Q1FY24 to earlier periods EBITDA Margin (%) PAT Margin (%) 49% 51% 47% 35% 35% 33% Q1FY23 Q4FY23 Q1FY24 Q1FY23 Q4FY23 Q1FY24 9
Slide 10: Financial Snapshot
Financial Snapshot Quarter ended Year ended 30-Jun-23 31-Mar-23 30-Jun-22 31-Mar-23 Revenue from operations 3,440.26 3,643.90 3,387.99 13,300.80 Other Income 100.59 107.55 108.98 445.52 Total Income 3,540.85 3,751.45 3,496.97 13,746.32 EBITDA 1,799.41 1,853.83 1,656.37 6,276.30 EBITDA Margin 50.82%
Slide 11: Notes and updates
Notes and updates ñThe Promoter Group, Jasti Property and Equity Holdings Private Limited (in their capacity as sole trustee of Jasti Family Trust), informed the Company that they executed a Share Purchase Agreement to sell 12,75,37,043 Equity shares representing 50.10% of the Voting share capital t
Slide 12: Company Background
Company Background PHARMA
Slide 13: Business Model
Business Model Process Custom Research Synthesis Contract Development And Manufacturing Operations (CDMO) Formulation Clinical Development Supplies Mfg Analytical & & Packaging Services 13
Slide 14: Brief Profile
Brief Profile BUSINESS OVERVIEW KEY STRENGTHS o Integrated CDMO company with strong o Preferred global outsourcing FINANCIAL OVERVIEW capabilities right from partner with capabilities o Standalone Revenues, EBITDA and process research & across the entire CDMO Adj. PAT of Rs 3541 Mn, Rs 1799 Mn devel
Slide 15: Brief Overview
Brief Overview Suven is an integrated Contract Development and Manufacturing Operations company Suven provides services to leading Global Life Science and Fine Chemical majors including Custom Synthesis, Process R&D, Scale Up and Contract Manufacturing of intermediates, APIs and formulations. Since
Slide 16: NCE based CDMO
Our Focus NCE based A full-fledged bio- pharmaceutical solutions CDMO provider for global pharmaceutical companies 16 16
Slide 17: Financial Approach
Financial Approach Consistently Low dividend debt paying Shareholder Prudent value creation utilisation of focus cash flows 17
Slide 18: Business Drivers
Business Drivers Industry Relationship An integrated research service provider with Leveraging on unmatched capabilities research capabilities Present across the to delivering NCE entire CDMO value research chain – State of the art intermediates & facilities located APIs across India and US 18
Slide 19: Business Drivers
Business Drivers Execution Capabilities Over 90% of Working with revenues from innovator companies regulated in developed markets markets having stringent regulations – Long term reflection of our commercial supply research skills Repeat business with the launch of owing to long product by global st
Slide 20: Multi Location Facilities
Multi Location Facilities o o 300 CM reactors (93) 500L to 10 KL GL/SS o GMP Intermediates Vizag, Andhra Pashamylaram, Telangana, India Banjara Hills, Hyderabad, India Suryapet, Telangana, India Pradesh, India API & Formulation Facility Corporate Office Intermediate Mfg. Facility o 307 KL reactor vo
Slide 21: Contact
Contact For queries and requests, please contact: Sunder Venkatraman Suven Pharmaceuticals Ltd Suven Pharmaceuticals Ltd Tel: +91 939 248 3011 # 8-2-334, SDE Serene Chambers, Email: info@suvenpharm.com For more info: www.suvenpharm.com 3rd Floor, Road No. 5, Avenue - 7, Banjara Hills, Hyderabad-500
Slide 22: Thank You
Thank You 6 SUVEN PHARMA
Suven Pharmaceuticals — Q1 FY24 Earnings Presentation on 6ix